Pao Group - PAOG STOCK NEWS

PAO Group, Inc. (OTC Pink: PAOG) provided a strategic update on its CBD pharmaceutical and nutraceutical initiatives. The company is advancing a cannabis extract therapy for respiratory disorders, particularly COPD, which has a projected market size of $14.1 billion by 2025. They have engaged a Contract Research Organization (CRO) to seek FDA approval for their COPD treatment, RespRx. PAOG also launched a range of CBD nutraceutical products and plans further development with Puration, Inc. under its RX label. The path to revenue encompasses significant challenges and expenses.

PAO Group, Inc. (OTC Pink: PAOG) provided a strategic update on its CBD pharmaceutical and nutraceutical initiatives. The company is developing a CBD-based therapy for respiratory diseases, including COPD, targeting a $14.1B market by 2025. Favorable preclinical results support the potential of their flagship product, RespRx, with a CRO engaged for FDA approval processes.

Additionally, PAOG is launching a line of CBD nutraceutical products, aiming for quick revenue growth. The company anticipates a partnership announcement with Puration, Inc. for further product development.

PAO Group, Inc. (OTC Pink: PAOG) highlighted research indicating that CBDA and CBGA, compounds found in hemp, can block a critical step the Covid virus uses to infect humans. These compounds inhibit the binding of the virus's spike proteins to human cells. PAOG holds intellectual property related to CBD extraction and is developing treatments for respiratory conditions, including Chronic Obstructive Pulmonary Disease (COPD), under the brand name RespRx. The company plans to publish a strategic update on January 28, 2022.

PAO Group, Inc. (OTC Pink: PAOG) has confirmed the development of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA), which is now focusing on an industrial hemp business cooperative named Farmersville Hemp. PURA has secured its first clients contributing to 2022 revenue goals, forecasting revenue of $1 million with potential growth to $10 million. PAOG owns a patented extraction method and is developing pharmaceutical and nutraceutical treatments. A partnership between PAOG and PURA will lead to CBD products under the Farmersville Hemp brand.

PAO Group, Inc. (OTC Pink: PAOG) announced that its RX branded full spectrum CBD products are now for sale at www.usmj.com. These products, which include CBD soft gels, tinctures, and muscle salves, utilize PAOG's proprietary extraction technology and have received positive consumer feedback. Additionally, the company has recently acquired an exclusive license for a CBD extraction patent. PAOG aims to develop both pharmaceutical and nutraceutical treatments based on this intellectual property, enhancing its market presence.

PAO Group, Inc. (OTC Pink: PAOG) has launched its RX branded full spectrum CBD products for direct-to-consumer sales through www.usmj.com. These include Softgels, Tinctures, and Muscle Salve, designed to enhance endocannabinoid activation and alleviate anxiety and pain. The company has developed these products based on proprietary extraction technology and has secured an exclusive license for a patented extraction method. This represents PAOG's entry into the nutraceutical market, with the RX line now available for purchase.

PAO Group, Inc. (OTC Pink: PAOG) has announced the acquisition of an exclusive license for a patented cannabis extraction process, enhancing its CBD intellectual property portfolio. This transaction is expected to close on December 3, 2021, and builds upon the company’s previous acquisition of related intellectual property. The patent will facilitate the development of pharmaceutical and nutraceutical treatments based on CBD extraction methods. This strategic move aims to bolster PAOG’s market position and expand its product offerings.

PAO Group, Inc. (OTC Pink: PAOG) has announced the acquisition of a license to a patented cannabis extraction process, enhancing its existing CBD intellectual property. This follows their previous acquisition of related intellectual property based on U.S. Patent No. 9,199,960. The company aims to develop pharmaceutical and nutraceutical treatments utilizing this intellectual property. The acquisition is expected to finalize in early December, potentially increasing the company's market footprint in the cannabis sector.

PAO Group, Inc. (OTC PINK: PAOG) announced plans to expand its pharmaceutical development pipeline, focusing on additional products alongside the ongoing RespRx CBD project for Chronic Obstructive Pulmonary Disease (COPD). The company is reviewing opportunities with its CRO partner and other firms to enhance and diversify its offerings. Some identified projects have the potential for rapid revenue generation as early as 2022. More details are expected in the coming weeks.